Atea Pharmaceuticals retains financial advisor to explore partnerships

Atea Pharmaceuticals (AVIR) announced that it has engaged Evercore to identify potential opportunities to enhance shareholder value, including the exploration of strategic partnerships related to its Phase 3-ready program for the treatment of hepatitis C virus, or HCV. The company has not set a timetable for the conclusion of its review and has not made any decisions at this time. The company does not intend to comment further with respect to this review unless or until its board of directors has approved a definitive course of action, the review process has concluded, or it is determined that other disclosure is appropriate. There is no assurance that this process will result in the completion of any specific transaction or outcome.